Mark Zucker
0000-0002-3388-379X
Memorial Sloan Kettering Cancer Center
1 paper found
Refreshing results…
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Missing publications? Search for publications with a matching author name.